/
OGEN
$0.59+$0.00 (+0.49%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.6M
5M shares
52-week range
$0.50 – $4.00
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Borrow rate
34.18%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1269.31
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $30.1K | $62.6K | $22.1M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$30.1K | −$62.6K | −$22.1M | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $6.0M | $12.1M | $22.1M | $10.6M | $10.1M | $15.5M | $4.1M | $2.39B |
| Operating income | −$10.0M | −$15.9M | −$26.6M | −$15.8M | −$14.4M | −$20.9M | −$10.6M | −$9.4M |
| EBITDA | −$9.9M | −$15.5M | −$26.6M | −$15.7M | −$14.2M | −$20.6M | −$10.5M | $762.2M |
| Net income | −$9.9M | −$15.6M | −$26.4M | −$15.7M | −$14.3M | −$20.7M | −$10.6M | −$9.8M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -45.62 | -22.10 | -28.05 | -8.09 | -7.11 | -9.18 | -1.60 | -4.56 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.69 | $-0.69–$-0.69 | 1 |
| 2027 | $0 | $-0.42 | $-0.42–$-0.42 | 1 |
| 2028 | $2M | $-0.39 | $-0.39–$-0.39 | 1 |
| 2029 | $45M | $0.29 | $0.29–$0.29 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.95
Price
$0.59
Implied upside
+230%
Peer comparison
Oragenics Inc.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
www.oragenics.com- Employees
- 3
- IPO / List date
- Jul 3, 2003
- HQ
- LAKEWOOD RANCH, FL
Held by traders on TradeandTell
No one on the platform currently holds OGEN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in OGEN as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-06-03 | 1-for-30reverse |
| 2023-01-23 | 1-for-60reverse |
| 2018-01-22 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded OGEN yet.
